A Phase 1/2 interventional study of Pemetrexed and Cisplatin in Malignant Pleural Mesotherioma, sponsored by Eli Lilly and Company. Completed at 7 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-11-06.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate
Duration of response
Progression free survival
Median survival time
1 year survival rate
Pulmonary function
QOL
Safety
Plasma concentration
The record gives a start of Oct 2005 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin